Is Infinity Pharmaceuticals, Inc. (INFIQ) a Buy, Sell, or Hold?
OTC : INFIQ
Infinity Pharmaceuticals, Inc.
$0.0001 USD
$0 (0.0%)
- Volume
- 109.4K
- Average Volume
- 26
- Market Capitalization
- $9.08K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.96
Company Overview
OTC
Vishal Mehta
Biotechnology
Healthcare
INFIQ
30
US
USD
Liquidity Metrics
-2.53
2.96
2.96
2.81
0.00
Sales & Valuation
$2.59M
0.00
0.00
0.00
-0.48
Profitability
-$0.5
-$44.37M
-1711.11%
-1711.11%
-3521.35%
-105.26%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
14 Analysts
%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
$9.83M
3.79
-0.22
2.96
-3521.35%
-154.02%
-497143.99%
-467695.02%
-1029 days
Company Executives
| Name | Title |
|---|---|
| Lawrence E. Bloch | Treasurer |
Poll Results
No votes yet today — be the first to share your view!
About Infinity Pharmaceuticals, Inc. (OTC:INFIQ) Stock
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and produ ... cts containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on March 7, 2024.
Frequently Asked Questions
-
What is the current Infinity Pharmaceuticals, Inc. (INFIQ) stock price?
-
Infinity Pharmaceuticals, Inc.(OTC:INFIQ) stock price is $0.0001 in the last trading session. During the trading session, INFIQ stock reached the peak price of $0.0001 while $0.00001 was the lowest point it dropped to. The percentage change in INFIQ stock occurred in the recent session was 0.0% while the dollar amount for the price change in INFIQ stock was $0.
-
INFIQ's industry and sector of operation?
-
The OTC listed INFIQ is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of INFIQ?
-
Lawrence E. Bloch | Treasurer
|
|
|
| -
How many employees does INFIQ have?
-
Number of INFIQ employees currently stands at 30. INFIQ operates from 1100 Massachusetts Avenue, Cambridge, MA 02138, US.
-
Link for INFIQ official website?
-
Official Website of INFIQ is: https://www.infi.com
-
How do I contact INFIQ?
-
INFIQ could be contacted at phone #+1 617 453 1000 and can also be accessed through its website. INFIQ operates from 1100 Massachusetts Avenue, Cambridge, MA 02138, US.
-
How many shares of INFIQ are traded daily?
-
The average number of INFIQ shares traded daily for last 3 months was 26.
-
What is the market cap of INFIQ currently?
-
The market value of INFIQ currently stands at $9.08K with its latest stock price at $0.0001